Depression is the third cause of disability worldwide. Many different antidepressants are available, but prescription is based on a trial and error principle, while personalization based on the individual’s genetic makeup can improve efficacy and reduce side effects. This dissertation demonstrated that genetic variants modulating the rapidity of antidepressant metabolism impact on treatment efficacy and side effects and they can facilitate the choice of the drug with the most favorable profile in each patient. Antidepressant response is probably influenced by multiple interacting genes and this dissertation identified groups of functionally related variants that may further contribute to treatment personalization
Introduction: Depression is responsible for the most part of the personal and socio-economic burden ...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments...
Depression is the third cause of disability worldwide. Many different antidepressants are available,...
Depression is the third cause of disability worldwide. Many different antidepressants are available,...
Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant pre...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Depression is the single largest contributor to non-fatal health loss and affects 322 million people...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background Major depressive disorder (MDD) has a high personal and socio-economic burden and > 60...
Published online: 08 February 2017About half of people who take antidepressants do not respond and m...
Background: There is sufficient evidence that interference of dopaminergic neurotransmission contrib...
Objective: The main goal of this work was to identify, describe, characterize, and classify the scie...
none3noDepression leads the higher personal and socio-economical burden within psychiatric disorders...
Introduction: Depression is responsible for the most part of the personal and socio-economic burden ...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments...
Depression is the third cause of disability worldwide. Many different antidepressants are available,...
Depression is the third cause of disability worldwide. Many different antidepressants are available,...
Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant pre...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Depression is the single largest contributor to non-fatal health loss and affects 322 million people...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background Major depressive disorder (MDD) has a high personal and socio-economic burden and > 60...
Published online: 08 February 2017About half of people who take antidepressants do not respond and m...
Background: There is sufficient evidence that interference of dopaminergic neurotransmission contrib...
Objective: The main goal of this work was to identify, describe, characterize, and classify the scie...
none3noDepression leads the higher personal and socio-economical burden within psychiatric disorders...
Introduction: Depression is responsible for the most part of the personal and socio-economic burden ...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments...